Amgen announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz and Zydus Pharmaceuticals. This decision affirms the permanent injunction entered by the district court prohibiting Sandoz and Zydus from making, using, selling, offering to sell, or importing each of their generic versions of Otezla until February 2028. Three of Amgen’s patents were the subject of the appeal. The appellate court upheld the validity of U.S. Patent No. 7,427,638, which claims pharmaceutical compositions of apremilast, and U.S. Patent No. 7,893,101, which claims a crystalline form of apremilast, but ruled against Amgen on U.S. Patent No. 10,092,541, which claims methods of treating psoriasis with apremilast according to a specific dosing schedule. Before trial, both Sandoz and Zydus acknowledged that their generic versions of Otezla infringe the asserted claims of U.S. Patent No. 7,427,638. In the U.S., Otezla is approved for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behcet’s Disease.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMGN:
- Amgen (NASDAQ:AMGN) Wins Patent Appeal on Key Psoriasis Drug
- Amgen price target lowered to $227 from $230 at Barclays
- Editas Medicine appoints Reeve as Chair of Board, Levy as new director
- InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA
- Early notable gainers among liquid option names on April 5th